In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

NuVasive publicly sells $341.2mm in convertible notes

Executive Summary

NuVasive Inc. (motion preservation and spinal fusion surgical devices) has netted $341.2mm through the public sale of six-year 2.75% convertible senior notes. The company had originally planned to offer $325mm in debt. At NuVasive’s election, the notes change into cash, stock, or a combination of the two. The initial conversion rate is 23.7344 shares per $1k principal amount of notes, equating to $42.13 each. (The stock is currently averaging $33.61.) NuVasive will use the majority of the proceeds to buy back up to $230mm of its 2.25% convertible notes due March 2013, as well as to pay for convertible note hedge transactions.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Medical Devices
    • Biomaterials
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • FOPO

Related Companies